Affimed NV (AFMDQ)

Affimed N.V. is a clinical-stage biopharmaceutical company focused on cancer immunotherapies, with research and development activities in the United States and Germany. The company’s pipeline includes AFM13, which has completed Phase 2 studies in CD30-positive lymphoma and peripheral T-cell lymphoma and has also been evaluated in a Phase Ib study in Hodgkin lymphoma. Its other programs include AFM24, a bispecific innate cell engager in Phase IIa development for advanced cancers, as well as AFM28 and AFM32, which are in preclinical development for acute myeloid leukemia and solid tumors, respectively. Affimed has entered into collaborations with Artiva Biotherapeutics, Roivant Sciences, and Genentech to advance selected product candidates and immunotherapy programs. The company, founded in 2000 and headquartered in Mannheim, Germany, was formerly known as Affimed Therapeutics B.V. and adopted its current name in 2014.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.